Cosmos Holdings Inc. (COSM)
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General